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Co-ingestion of a protein hydrolysate and amino acid mixture with
carbohydrate improves plasma glucose disposal in patients with
type 2 diabetes1–3
Ralph JF Manders, Anton JM Wagenmakers, René Koopman, Antoine HG Zorenc, Paul PCA Menheere,
Nicolaas C Schaper, Wim HM Saris, and Luc JC van Loon
ABSTRACT
Background: Although insulin secretion after carbohydrate inges-
tion is severely impaired in patients with type 2 diabetes, amino acid
and protein co-ingestion can substantially increase plasma insulin
responses.
Objective: We investigated insulin responses and the subsequent
plasma glucose disposal rates after the ingestion of carbohydrate alone
(CHO) or with a protein hydrolysate and amino acid mixture
(CHOPRO) in patients with a long-term diagnosis of type 2 diabetes.
Design: Ten type 2 diabetic patients [mean (SEM) age: 62 2 y;
body mass index (kg/m2): 27  1] and 9 healthy control subjects
(age: 58 1 y; body mass index: 27 1) participated in 2 trials in
which the plasma insulin response was measured after the ingestion
of 0.7 g carbohydrate · kg1 · h1 with or without 0.35 g · kg1 · h1
of a mixture that contained a protein hydrolysate, leucine, and phe-
nylalanine. Continuous infusions with [6,6-2H2]glucose were then
given to investigate plasma glucose disposal.
Results: Plasma insulin responses were higher by 299  64% and
132  63% in the CHOPRO trial than in the CHO trial in the
diabetic patients and the matched control subjects, respectively (P
0.001). The subsequent plasma glucose responses were reduced by
28 6% and 33 3% in the CHOPRO trial than in the CHO trial
in the diabetic patients and the matched control subjects, respec-
tively (P  0.001). The reduced plasma glucose response in the
diabetic patients was attributed to a 13  3% increase in glucose
disposal (P 0.01).
Conclusions: The combined ingestion of carbohydrate with a pro-
tein hydrolysate and amino acid mixture significantly increases de
novo insulin production in patients with a long-term diagnosis of type 2
diabetes. The increased insulin response stimulates plasma glucose dis-
posal and reduces postprandial glucose concentrations. Am J Clin
Nutr 2005;82:76–83.
KEY WORDS Glucose disposal, protein hydrolysate, leucine,
phenylalanine, metabolism, type 2 diabetes
INTRODUCTION
The stimulating effect of the combined intake of carbohydrate
and protein on plasma insulin release was reported in the 1960s
(1, 2) and has since been confirmed in healthy subjects (3) and in
patients with type 2 diabetes (4–6). Furthermore, intravenous
infusion of free amino acids was reported to increase insulin
secretion (7–9). In agreement with these findings, various in vitro
studies with incubated  cells have attributed strong insulino-
tropic properties to arginine, leucine, and phenylalanine (10–
17). We have performed various in vivo studies in which we
defined an optimal insulinotropic amino acid and protein mixture
containing leucine, phenylalanine, and a protein hydrolysate that
has repeatedly been shown to augment the insulin response by an
additional 100% in healthy subjects (18, 19). Nutritional inter-
ventions that effectively stimulate endogenous insulin secretion
could be of particular significance in patients with type 2 diabe-
tes. An increase in endogenous insulin secretion could increase
blood glucose disposal and thus improve glucose homeostasis.
Moreover, preventing or reducing the postprandial rise in blood
glucose concentration that follows carbohydrate intake could
reduce the risk of developing diabetic and cardiovascular com-
plications (20, 21). Furthermore, the combined administration of
amino acids and protein with carbohydrate, which leads to a state
of hyperinsulinemia and hyperaminoacidemia, may represent an
effective strategy to inhibit proteolysis and to stimulate protein
synthesis (22, 23). This outcome would be of particular interest,
because muscle protein breakdown rates are markedly elevated
in uncontrolled diabetes (24).
In patients with a long-term diagnosis of type 2 diabetes,
hyperglycemia is not accompanied by a compensatory hyperin-
sulinemia. As such, it is generally assumed that the capacity of
the  cell to secrete insulin is severely impaired as the result of
several defects (25). These defects, which are all indicative of a
progressive insensitivity of the  cell to glucose, include a re-
duced early-insulin secretory response to oral glucose, a reduced
ability of the  cell to compensate for the degree of insulin
resistance, a decline in the glucose-sensing ability of the  cell,
and a shift to the right in the dose-response curve relating glucose
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and insulin secretion (26). All of these defects involve glucose-
sensing and -signaling pathways in the  cell. Although insulin
secretion in response to carbohydrate intake is impaired in pa-
tients with type 2 diabetes, we recently showed that co-ingestion
of a protein and amino acid mixture can increase the plasma
insulin response 2–3-fold (27). Although such nutritional inter-
ventions can effectively stimulate endogenous insulin secretion
in patients with a long-term diagnosis of type 2 diabetes, the
clinical significance of these interventions in regard to blood
glucose homeostasis remains to be established.
In the present study, we investigated the insulinotropic prop-
erties of a combination of a mixture of protein hydrolysate,
leucine, and phenylalanine with carbohydrate and the glucose dis-
posal rate after its ingestion in patients with a long-term diagnosis of
type 2 diabetes and in healthy, matched control subjects.
SUBJECTS AND METHODS
Subjects
Ten male patients with a long-term diagnosis of type 2 diabetes
and 10 healthy, matched control subjects were selected to par-
ticipate in the present study. The baseline characteristics of the
subjects are shown in Table 1. Exclusion criteria were impaired
renal or liver function, obesity [body mass index (in kg/m2)
35], cardiac disease, hypertension, diabetic complications, and
exogenous insulin therapy. All except one of the type 2 diabetic
patients (n  9) were using oral antidiabetic agents (metformin
alone or in combination with sulfonylureas). One control subject
withdrew from the experiment for personal reasons. In the type
2 diabetic patients, any medication being used was withheld for
2 d before the screening process. The subjects were screened for
glucose intolerance and type 2 diabetes by use of a standard
oral-glucose-tolerance test according to the World Health Orga-
nization criteria of 1999 (28). All subjects were informed about
the nature and the risks of the experimental procedures before
their written informed consent was obtained. All clinical trials
were approved by the local medical ethical committee.
Screening
Before selection into the study, all subjects were given an
oral-glucose-tolerance test. The subjects arrived at the laboratory
at 0800 by car or public transportation after having fasted over-
night. A blood sample was collected from the fasting subjects,
after which a bolus of 75 g glucose (dissolved in 250 mL water)
was ingested (t 0 min). After 120 min, a second blood sample
was obtained. Plasma glucose concentrations were measured to
determine glucose intolerance and type 2 diabetes according to
the World Health Organization criteria of 1999 (28). In addition,
basal fasting plasma glucose and insulin concentrations were
used to assess whole-body insulin resistance with the homeosta-
sis model assessment insulin resistance index (29), which was
calculated as the product of basal fasting plasma glucose
(mmol/L) and insulin (mU/L) concentrations divided by 22.5.
Medication, diet, and activity before testing
Medication that stimulates insulin production or secretion
(sulfonylurea derivatives) was withheld for 2 d before each test
to prevent confounding effects on amino acid–induced insulin
secretion. The use of insulin sensitizers (metformin) was contin-
ued to support the benefits of increasing endogenous insulin
secretion on glucose homeostasis. All subjects maintained nor-
mal dietary and physical activity patterns throughout the entire
experimental period. In addition, the subjects refrained from
heavy physical labor and exercise for3 d before each trial and
filled out a food-intake diary for 2 d before the first trial to keep
their dietary intake as identical as possible before the second trial.
The evening before each trial, the subjects received a standard-
ized meal (43.80 kJ/kg body wt that consisted of 60% of energy
as carbohydrate, 28% of energy as fat, and 12% of energy as
protein).
Design
Each subject participated in 2 trials, separated by a 2-wk pe-
riod, in which the plasma insulin response and subsequent
plasma glucose disposal rate were measured after the ingestion of
2 different beverage compositions (CHO, carbohydrate only; or
CHOPRO, carbohydrate and a mixture that contained a protein
hydrolysate and the free amino acids leucine and phenylalanine).
The subjects were placed in a supine position and remained
inactive for 3 h. Drinks were provided in a randomized order and
a double-blind fashion. The beverages were flavored to make the
taste comparable in both trials (see below).
Protocol
The subjects reported to the laboratory at 0800 after an over-
night fast. A catheter (Baxter BV, Utrecht, Netherlands) was
inserted into an antecubital vein for the isotope infusion. Another
catheter was inserted into a dorsal vein on the contralateral hand
and was placed in a hot-box (60 °C) for arterialized blood sam-
pling. After 10 min, a blood sample was collected from the
TABLE 1
Subject characteristics1
Control group
(n 9)
Type 2 diabetic group
(n 10)
Age (y) 58.2 1.0 61.5 2.3
Body weight (kg) 84.89 2.86 81.8 3.89
Height (m) 1.76 0.02 1.73 0.02
BMI (kg/m2) 27.49 1.07 27.19 0.97
Basal plasma glucose
(mmol/L)
5.31 0.12 10.71 0.562
Plasma
glucoseOGTTI20
(mmol/L)3
4.98 0.41 20.01 1.142,4
Basal plasma insulin
(mU/L)
6.44 0.90 10.30 1.59
Hb A1c (%) 5.10 0.13 7.49 0.382
HOMA-IR 1.52 0.22 5.02 0.962
Diagnosed with type 2
diabetes (y)
NA 11 2
Medication NA Metformin or SU
derivatives
1 All values are x  SEM. OGTT, oral-glucose-tolerance test; Hb A1c,
glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin
resistance (29); NA, not applicable; SU, sulfonylureas.
2 Significantly different from control group, P 0.01 (t test comparing
patient and control group).
3 Plasma glucose concentration 2 h after ingestion of 75 g glucose.
4 Significantly different from basal values, P  0.01 (t test comparing
pre- and post-OGTT values).
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resting subjects (t  0 min). After the administration of an in-
travenous bolus of 13.5mol [6,6-2H2]glucose/kg, a continuous
infusion of 277 3 nmol · kg1 · min1 of [6,6-2H2]glucose was
started via a calibrated IVAC 560 pump (IVAC Corp, San Diego,
CA) and continued until t 180 min. At t 0 min, the subjects
drank an initial bolus (2 mL/kg) of the test drink (CHO or
CHOPRO). Repeated boluses (2 mL/kg) were ingested every
15 min until t  165 min. Blood samples were drawn every 15
min during the first hour and then every 30 min until t 180 min
for the measurement of plasma glucose, glucose enrichment, and
insulin. In addition, proinsulin and C-peptide concentrations
were measured in the blood samples that were collected at t 0,
60, 120, and 180 min.
Beverages
The subjects received repeated boluses of 2 mL/kg to ensure a
given dose of 0.7 g carbohydrate · kg1 · h1 (50% as glucose and
50% as maltodextrin) with or without 0.35 g · kg1 · h1 of a
protein hydrolysate and amino acid mixture (50% as casein hy-
drolysate, 25% as free leucine, and 25% as free phenylalanine)
every 15 min until t 165 min. Glucose and maltodextrin were
obtained from AVEBE (Veendam, Netherlands), crystalline
amino acids were from BUFA (Uitgeest, Netherlands), and the
casein protein hydrolysate was prepared by DSM Food Special-
ties (Delft, Netherlands). The casein hydrolysate (Insuvital;
DSM Food Specialties) was obtained by enzymatic hydrolysis of
sodium caseinate with the use of a neutral protease and a prolyl-
specific endoproteinase. Both drinks were uniformly flavored by
the addition of 0.2 g sodiumsaccharinate, 1.8 g citric acid, and 5 g
of a cream vanilla flavor (Quest International, Naarden, Nether-
lands) for each 1 L of beverage.
Isotope tracer calculations
The glucose tracer (99% enriched; Cambridge Isotope labo-
ratories, Andover, MA) was first dissolved in 0.9% saline. The
glucose tracer concentration in the infusates averaged 22 0.4
mmol/L. The [6,6-2H2]glucose infusion rate averaged 277  3
nmol · kg1 · min1. Plasma glucose enrichments are expressed
as tracer/tracee ratios. The rate of appearance (Ra) and rate of
disappearance (Rd) of glucose were calculated with the use of the
single-pool non–steady state Steele equations (30) adapted for
stable-isotope studies as described elsewhere (31).
Ra  {F  V C2  C1/2E2  E1/t2  t1}/
E2  E1/2 (1)
Rd  Ra  V  C2  C1/t2  t1 (2)
where F is the infusion rate (in mol · kg1 · min1); V is the
distribution volume for glucose (160 mL/kg); C1 and C2 are the
glucose concentrations (in mmol/L) at time 1 (t1) and 2 (t2),
respectively; and E1 and E2 are the plasma glucose enrichments
(tracer/tracee ratios) at time 1 and 2, respectively.
Blood sample analysis
Blood (10 mL) was collected in EDTA-containing tubes and
centrifuged at 1000  g for 10 min at 4 °C. Aliquots of plasma
were immediately frozen in liquid nitrogen and stored at80 °C
until analyzed. Glucose concentrations (Uni Kit III; Roche,
Basel, Switzerland) were analyzed with the COBAS FARA
semiautomatic analyzer (Roche). Plasma insulin, proinsulin, and
C-peptide concentrations were assayed with a modified, solid-
phase, 2-site fluoroimmunometric assay based on a direct sand-
wich technique (DELFIA method; Perkin Elmer, Turku, Fin-
land). To measure the glycated hemoglobin content, a 3-mL
blood sample was collected in EDTA-containing tubes and was
analyzed by HPLC (Bio-Rad Diamat, Munich, Germany). After
derivatization of the plasma samples, plasma [6,6-2H2]glucose
enrichment was measured by electron ionization gas chromatog-
raphy–mass spectrometry (Finnigan INCOS-XL; Finnigan Mat,
Ilemel, Hemstead, United Kingdom).
Statistics
Data are expressed as means SEMs. The plasma responses
were calculated as the area under the curve minus baseline val-
ues. To compare plasma metabolite concentrations and tracer
kinetics over time between trials, a two-way repeated-measures
analysis of variance (ANOVA) was performed. Subgroups were
analyzed further whenever significant time-by-treatment inter-
actions were observed. Changes in time within each group were
checked for statistical significance with the use of a one-way
repeated-measures ANOVA. When an F ratio was significant, a
Scheffe’s post hoc test was performed to locate specific differ-
ences. For non-time-dependent variables, a multiway ANOVA
alone or with a Student’s t test for unpaired observations was
used. Significance was set at P  0.05. All calculations were
performed with STATVIEW 5.0 (SAS Institute Inc, Cary, NC).
RESULTS
Insulin
Plasma insulin concentrations in subjects that had fasted over-
night were similar in both groups and in both trials. Insulin
concentrations increased significantly in both groups after the
ingestion of carbohydrate alone and carbohydrate with the pro-
tein and amino acid mixture (P 0.001; Figure 1A). A repeated-
measures ANOVA showed a significant time-by-treatment in-
teraction for plasma insulin concentrations (P 0.01). After t
60 min, plasma insulin concentrations in the diabetes group were
higher in the CHOPRO trial than in the CHO trial (P 0.05).
No significant differences were found between trials in the con-
trol group. After the insulin response was expressed as the area
under the curve (minus baseline values), significantly greater
plasma insulin responses were observed in the CHOPRO trial
than in the CHO trial in both groups (P  0.01, Figure 1B).
Plasma insulin responses were 299  64% and 132  63%
greater in the CHOPRO trial than in the CHO trial in the
diabetes and control groups, respectively (P 0.01).
C-peptide and proinsulin
Plasma C-peptide concentrations in fasting subjects were sim-
ilar in both groups. A repeated-measures ANOVA showed a
significant time-by-treatment interaction for plasma C-peptide
concentrations (P  0.01). In both trials, C-peptide concentra-
tions increased significantly over time (P  0.05; Figure 2).
After t60 min, plasma C-peptide concentrations in the diabetes
group were significantly higher in the CHOPRO trial than in
the CHO trial (P 0.05). When expressed as the area under the
curve, significantly greater C-peptide responses were observed
in the CHOPRO trial than in the CHO trial in both groups (P
0.01). Plasma C-peptide responses were 9818% and 5626%
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greater in the CHOPRO trial than in the CHO trial in the
diabetes and control groups, respectively (P  0.01). Plasma
C-peptide concentrations correlated well with plasma insulin
concentrations (r 0.89, P 0.001).
Plasma proinsulin concentrations in fasting subjects were
higher in the type 2 diabetes group than in the normoglycemic
control subjects (28.3  2.9 mmol/L compared with 7.5  0.5
mmol/L, respectively P  0.01). In both trials, proinsulin con-
centrations increased significantly over time (P0.01; Figure 2)
and showed a significant time-by-treatment interaction (P 
0.01). After t 120 min, plasma proinsulin concentrations in the
diabetes group were higher in the CHOPRO trial than in the
CHO trial (P 0.05). No significant differences were observed
between trials in the control group. When expressed as the area
under the curve, significantly greater proinsulin responses were
observed in the CHOPRO trial than in the CHO trial in both
groups (P 0.05). The plasma proinsulin responses were 151
28% and 84  37% greater in the CHOPRO trial than in the
CHO trial in the diabetes and the control groups, respectively
(P  0.05). Plasma proinsulin concentrations correlated with
both plasma insulin and plasma C-peptide concentrations (r 
0.79 and r 0.85, respectively; P 0.001)
FIGURE 1. Mean (SEM) plasma insulin concentrations (A) and re-
sponses (B) over a 3-h period after the ingestion of carbohydrate (CHO; open
symbols) or carbohydrate and a protein hydrolysate and amino acid mixture
(CHOPRO; filled symbols) in patients with type 2 diabetes (n 10) and in
healthy, matched control subjects (n  9). (A) Insulin concentrations in-
creased significantly over time in both groups and trials, P  0.001. No
significant differences were found between trials in the control group. There
was a significant time  treatment interaction for insulin (P  0.01). *Sig-
nificantly different from the CHO trial in the diabetes group, P  0.05
(Scheffe’s adjustment). (B)*Significantly different from the CHO trial, P
0.05 (ANOVA).
FIGURE 2. Mean (SEM) plasma C-peptide and proinsulin concentra-
tions over a 3-h period after the ingestion of carbohydrate (CHO) or carbo-
hydrate and a protein hydrolysate and amino acid mixture (CHOPRO) in
patients with type 2 diabetes (n10) and in healthy, matched control subjects
(n  9). We found a significant time  treatment interaction for C-peptide
and proinsulin (P 0.01 for all). C-peptide concentrations increased signif-
icantly over time in both trials and groups, P  0.05. After t  60 min,
C-peptide concentrations were significantly different between trials in the
diabetes group (Scheffe’s adjustment); no significant differences were found
between trials in the control group. Proinsulin concentrations increased sig-
nificantly over time in both trials and groups, P 0.01. After t 120 min,
proinsulin concentrations were significantly different between trials in the
diabetes group (Scheffe’s adjustment); no significant differences were found
between trials in the control group. *Significantly different from the CHO
trial, P 0.05.
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Glucose
Plasma glucose concentrations in fasting subjects were higher
in the type 2 diabetic patients than in the normoglycemic control
subjects (9.7  0.3 mmol/L compared with 5.7  0.1 mmol/L,
respectively; P 0.01). A repeated-measures ANOVA showed
a significant time-by-treatment interaction for plasma glucose
concentrations (P 0.01). In the type 2 diabetic patients, plasma
glucose concentrations in the CHO trial increased after carbo-
hydrate ingestion until t 150 min, after which values reached
a plateau. In the CHOPRO trial, glucose concentrations in-
creased significantly during the first 90 min (P  0.01), after
which they either reached a plateau or tended to decline (Figure
3A). At t  180 min, the plasma glucose concentration was
significantly lower in the CHOPRO trial than in the CHO trial
(P  0.05) for the type 2 diabetes group. In the control group,
plasma glucose concentrations slightly increased during the first
60 min in both trials and then returned to baseline levels over the
next 2 h (Figure 3A). Plasma glucose concentrations were sig-
nificantly higher in the type 2 diabetic patients than in the
matched control subjects (P0.05). After expressing the plasma
glucose response as the area under the curve, we observed a
significantly higher plasma glucose response in the type 2 dia-
betic patients than in the matched normoglycemic control sub-
jects (P 0.001; Figure 3B). In both groups, significantly lower
plasma glucose responses were observed in the CHOPRO trial
than in the CHO trial (P0.001; Figure 3B). The plasma glucose
response was 28  6% and 33  3% lower in the CHOPRO
trial than in the CHO trial in the diabetes and matched control
groups, respectively (P 0.001).
Glucose tracer kinetics
In the type 2 diabetes group, the plasma glucose Ra was stable
over the entire testing period and averaged 42.4 0.8 and 41.2
1.1 mol · kg1 · min1 in the CHO and CHOPRO trials,
respectively. In the control group, the plasma glucose Ra was
also stable and averaged 39.8 0.7 and 37.9 0.8 mol · kg1
· min1 in the CHO and CHOPRO trials, respectively (Table
2 and Figure 4A and B). No significant differences in the plasma
glucose Ra were observed between trials or groups.
The glucose Rd increased over time in both trials and in both
groups (P0.05; Figure 4C and D). In the diabetes group, the Rd
averaged 19.7 2.4 and 20.4 2.8 mol · kg1 · min1 at t
30 min and increased over time to reach 45.1 1.8 and 45.4
3.6 mol · kg1 · min1 in the CHO and CHOPRO trials,
respectively (Figure 4C). In the control group, the Rd averaged
14.7 1.4 and 19.4 1.7mol · kg1 · min1 at t 30 min and
increased to 45.4 2.4 and 44.8 2.2mol · kg1 · min1 in the
CHO and CHOPRO trials, respectively (Figure 4D). The in-
crease in the Rd over time was significantly different between
groups (P 0.05).
Plasma glucose disposal, expressed as the percentage of the
appearing glucose that disappears from the circulation, was sig-
nificantly lower in the diabetic patients than in the matched
control subjects (P  0.001; Table 2). In the diabetes group,
plasma glucose disposal was 12.5  3.1% higher in the
CHOPRO trial than in the CHO trial (P 0.01). In the control
group, plasma glucose disposal was not significantly improved
in the CHOPRO trial (3.4 2.2%; P 0.2; Table 2).
In the diabetes group, the glucose disposal rate was signifi-
cantly improved by 15.8 g (	88 mmol) over the 150-min period
in the CHOPRO trial compared with the CHO trial (P 0.01).
In the control group, an additional 11.7 g (	65 mmol) glucose
was disposed of during the 150-min period in the CHOPRO
trial compared with the CHO trial (P 0.2).
DISCUSSION
The present study showed that co-ingestion of carbohydrate
with a mixture containing casein hydrolysate, leucine, and phe-
nylalanine substantially increased insulin secretion when com-
pared with the ingestion of carbohydrate alone. The substantial
FIGURE 3. Mean (SEM) plasma glucose concentrations (A) and re-
sponses (B) over a 3-h period after the ingestion of carbohydrate (CHO; open
symbols) or carbohydrate and a protein hydrolysate and amino acid mixture
(CHOPRO; filled symbols) in patients with type 2 diabetes (n 10) and in
healthy, matched control subjects (n  9). (A) Glucose concentrations in-
creased significantly over time in both trials for the diabetic patients, P 
0.01. There was a significant time treatment interaction for glucose, P
0.01. *Significantly different from the CHO trial for both groups, P  0.05
(Scheffe’s adjustment). (B)*,#Significantly different from the CHO trial
(ANOVA): *P 0.05, #P 0.001.
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3–4-fold greater insulin response significantly improved post-
prandial glucose disposal and resulted in lower plasma glucose
concentrations in type 2 diabetic patients. This study indicates
that nutritional interventions that improve endogenous insulin
secretion can be practical and effective tools in the treatment of
type 2 diabetes.
The synergistically stimulating effect of the combined inges-
tion of carbohydrate and intact protein on plasma insulin release
was first reported in the late 1960s (1, 2) and was later confirmed
in both healthy subjects (3) and type 2 diabetic patients (4–6).
Floyd et al (7–9, 32) investigated the effects of intravenous in-
fusions of various amino acids on plasma insulin secretion and
reported that arginine, leucine, and phenylalanine were the most
insulinotropic amino acids. We have confirmed many of these
findings after testing the oral administration of these amino acids
in combination with carbohydrate (18, 19). Consequently, we
defined a practical and optimal insulinotropic amino acid and
protein mixture composed of a protein hydrolysate, free leucine,
and phenylalanine (18, 19). Recently, we investigated the insu-
linotropic properties of this mixture in patients with a long-term
diagnosis of type 2 diabetes and reported a 189% greater plasma
insulin response in these patients when the mixture was co-
ingested with carbohydrate than when carbohydrate was in-
gested alone (27). Although that study clearly showed that en-
dogenous insulin secretion can be substantially increased in
patients with a long-term diagnosis of type 2 diabetes, the clinical
relevance of these findings had not yet been established. There-
fore, in the present study, we investigated plasma glucose dis-
posal after the ingestion of carbohydrate with or without the
addition of such an insulinotropic protein hydrolysate and amino
acid mixture in healthy subjects and in type 2 diabetic patients.
The patients with type 2 diabetes who were selected for this
study had been diagnosed with type 2 diabetes for10 y. Basal
fasting glucose concentrations, oral-glucose-tolerance test val-
ues, glycated hemoglobin content, and the homeostasis model
assessment insulin resistance index values confirmed their type
2 diabetic state (Table 1). Hyperinsulinemia, a compensatory
response to the prevailing hyperglycemia, was no longer present
in these patients (Table 1 and Figure 1). After ingestion of only
carbohydrate in the CHO trial, insulin responses were substan-
tially lower in the diabetic patients than in the control subjects
(Figure 1B). This finding clearly illustrates the reduced sensitiv-
ity of the  cell to glucose in the type 2 diabetic state (26).
Interestingly, co-ingestion of carbohydrate with the protein hy-
drolysate and amino acid mixture in the CHOPRO trial signif-
icantly increased the plasma insulin response by 299 64% and
132 63% in the diabetic patients and the normoglycemic con-
trol subjects, respectively (P  0.01; Figure 1B). The insulin
response in the CHOPRO trial in the type 2 diabetic patients
was similar to the insulin response reported in the CHO trial in the
healthy subjects (Figure 1B). In other words, although the sen-
sitivity of the pancreas to carbohydrate intake is significantly
reduced in patients with a long-term diagnosis of type 2 diabetes,
the capacity to secrete insulin in response to other stimuli (such
as amino acids) remains intact. Therefore, the defects in the
insulin response after the ingestion of a meal in these patients are
mainly attributed to the reduced sensitivity of the  cell to glu-
cose and not to an overall defect in the capacity to produce or to
secrete insulin.
To confirm that the elevated plasma insulin concentrations in
the CHOPRO trial are indeed secondary to increased insulin
production, we measured plasma C-peptide and proinsulin con-
centrations according to the method of Hovorka and Jones (33).
In the process of insulin production, the precursor proinsulin is
cleaved into insulin and the 31-kD residue connecting peptide
(C-peptide). Insulin, C-peptide, and a small amount of residual
proinsulin are stored in the secretory granules of the  cell until
secretion (34). In the present study, we observed a significant
increase in plasma C-peptide and proinsulin concentrations over
time in all trials (Figure 2). Significantly greater plasma
C-peptide responses were observed in the CHOPRO than in the
CHO trial (98 18% and 56 26% in the diabetic patients and
healthy control subjects, respectively; P  0.01). Similarly,
plasma proinsulin responses were also 15128% and 84 37%
greater in the CHOPRO trial than in the CHO trial in the
diabetes and control groups, respectively (P  0.05). Both
C-peptide and proinsulin concentrations correlated well with
plasma insulin concentrations (r  0.89 and r  0.79, respec-
tively: P 0.001). Thus, these data further support the observa-
tion that co-ingestion of carbohydrate with the protein and amino
acid mixture in the CHOPRO trial effectively stimulates de
novo insulin production.
In response to the increased insulin production and secretion
rate in the CHOPRO trial, plasma glucose concentrations were
significantly decreased when compared with values observed in
the CHO trial (Figure 3A). In the CHOPRO trial, plasma glu-
cose responses were decreased by as much as 28 6% and 33
3% in the diabetic patients and normoglycemic control subjects,
respectively, compared with responses in the CHO trial (P 
0.001). This decrease in the plasma glucose response is much
more prominent than in our earlier observations (27), which can
be explained by the longer trial duration in the present study.
Interventions that effectively reduce the postprandial rise in
plasma glucose concentrations after carbohydrate intake are of
clinical significance and have been associated with a reduced risk
of developing diabetic and cardiovascular complications (20,
21). Many food components or pharmacologic agents that effec-
tively lower postprandial glucose concentration after meal in-
gestion inhibit gastric emptying or intestinal uptake of glucose or
both (35–37). In the present study, we applied a continuous
TABLE 2
Plasma glucose kinetics1
CHO CHO PRO
Control group (n 9)
Ra (mol  kg1  min1) 39.8 0.7 37.9 0.8
Rd (mol  kg1  min1) 36.2 1.7 35.7 1.3
Glucose disposal (Rd as % of Ra) 91 4 94 3
Time for Rd to match Ra (min) 90 8 75 62
Type 2 diabetic group (n 10)
Ra (mol  kg1  min1) 42.4 0.8 41.2 1.1
Rd (mol  kg1  min1) 30.3 1.3 33.2 1.5
Glucose disposal (Rd as % of Ra) 72 33 81 32,3
Time for Rd to match Ra (min) 179 84 135 92,4
1 All values are x SEM of [6.6-2 H2]glucose tracer rate of appearance
(Ra) and disappearance (Rd) and Rd expressed as percentage of Ra over the
entire 150-min period. CHO, carbohydrate; CHO PRO, carbohydrate and
protein mixture.
2 Significantly different from CHO trial, P  0.01 (t test comparing
trials within each group).
3,4 Significantly different from control group (t test comparing trials
between groups): 3P 0.001, 4P 0.01.
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infusion of a [6,6-2H2]glucose tracer to measure the Ra of glu-
cose in the circulation. Plasma glucose Ras were similar in both
groups and trials and remained constant throughout the trials
(Table 2, Figure 4A and B). This finding indicates that inhibition
of gastrointestinal uptake of glucose is not responsible for the
observed decline in the postprandial blood glucose response after
co-ingestion of carbohydrate with the protein and amino acid
mixture.
Whereas the plasma glucose Ra remained stable throughout
the trials, the plasma glucose Rd from the circulation signifi-
cantly increased over time in both trials (Figure 4; P 0.01). In
contrast with the Ra values, the plasma glucose Rd was strikingly
different between the diabetic patients and the healthy, matched
control subjects (Figure 4C and D). Whereas Rd values increased
exponentially in the control subjects, a more gradual rise in the
glucose Rd was observed in the diabetic patients (P  0.01). It
took about twice as long in the diabetic patients as in the healthy
subjects for the plasma glucose Ra to be matched by its Rd (P
0.01). Consequently, plasma glucose disposal (calculated as Rd
expressed as a percentage of Ra) was significantly lower in the
diabetic patients than in the normoglycemic control subjects
(Table 2; P 0.01). In both groups, the time for the Rd to match
the Ra was significantly reduced in the CHOPRO trial (Table
2; P  0.01). Accordingly, plasma glucose disposal after co-
ingestion of carbohydrate with the protein and amino acid mix-
ture improved plasma glucose disposal by 13 3% (P 0.01)
and 3  2% (P  0.2) in diabetic patients and healthy control
subjects, respectively.
In conclusion, ingestion of a protein hydrolysate, leucine, and
phenylalanine mixture can substantially augment insulin re-
sponses after carbohydrate intake. In patients with a long-term
diagnosis of type 2 diabetes, co-ingestion of carbohydrate with
such a mixture can induce a 3–4-fold greater plasma insulin
response than ingestion of carbohydrate alone. This response
effectively improves plasma glucose disposal and thereby re-
duces the postprandial plasma glucose concentration. The com-
bined ingestion of an amino acid and protein mixture with car-
bohydrate represents an effective interventional strategy in the
treatment of type 2 diabetes.
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FIGURE 4. Mean (SEM) plasma glucose rate of appearance (Ra: A and B) and disappearance (Rd: C and D) over time in patients with type 2 diabetes
(A and C) and in healthy, matched control subjects (B and D) after the ingestion of carbohydrate (CHO) or carbohydrate and a protein hydrolysate and amino
acid mixture (CHOPRO) in patients with type 2 diabetes (n 10) and in healthy, matched control subjects (n 9). No significant differences in Ra were
observed between trials or groups. Glucose Rd increased over time in both trials in both groups, P0.05. The increase in Rd over time was significantly different
between groups (P 0.05) but not between trials. *Significantly different from t 30 min, P 0.05.
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